Research Article
Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center
Table 3
Administered vaccines against SARS-CoV-2.
| | No. | % |
| Entire cohort | 156 | 100 | Unvaccinated | 10 | 6.4 | Unknown vaccination status | 3 | 1.9 | Vaccinated/number of vaccinations | | | First vaccine | 143 | 91.7 | Vaxzevria® (AstraZeneca AB) | 12 | | Comirnaty® (BioNTech GmbH) | 114 | | Jcovden® (Johnson & Johnson) | 4 | | Spikevax® (Moderna Biotech) | 13 | | Second vaccine | 136 | 87.1 | Vaxzevria® | 4 | | Comirnaty® | 113 | | Spikevax® | 18 | | Unknown | 1 | | Third vaccine | 113 | 72.4 | Vaxzevria® | 3 | | Comirnaty® | 83 | | Spikevax® | 25 | | Unknown | 2 | | Fourth vaccine | 11 | 7.1 | Comirnaty® | 8 | | Spikevax® | 2 | | Unknown® | 1 | |
|
|
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
|